Thomas Schall
Director/Board Member at IMMUNEERING CORPORATION
Net worth: 4 147 $ as of 30/04/2024
Thomas Schall active positions
| Companies | Position | Start | End |
|---|---|---|---|
| IMMUNEERING CORPORATION | Director/Board Member | 12/03/2024 | - |
Career history of Thomas Schall
Former positions of Thomas Schall
| Companies | Position | Start | End |
|---|---|---|---|
| CHEMOCENTRYX, INC. | Director/Board Member | 01/10/1997 | 01/04/2012 |
| Chief Executive Officer | 01/10/1997 | 20/10/2022 | |
| Chairman | 01/04/2012 | 20/10/2022 | |
| Founder | 01/10/1997 | 20/10/2022 | |
| President | 01/10/1997 | 20/10/2022 | |
| DNAX Research, Inc. | Corporate Officer/Principal | 01/12/1993 | 01/01/1997 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | - | - |
Training of Thomas Schall
| Stanford University | Doctorate Degree |
| Northern Illinois University | Undergraduate Degree |
Statistics
International
| United States | 7 |
Operational
| Director/Board Member | 2 |
| Chief Executive Officer | 1 |
| Chairman | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| IMMUNEERING CORPORATION | Health Technology |
| Private companies | 3 |
|---|---|
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
| DNAX Research, Inc. |
- Stock Market
- Insiders
- Thomas Schall
- Experience
